A €4 million investment from majority shareholder Maabarot Products will help French seaweed and algae specialist Algaia boost development and install new speciality extraction units, says the firm.
Dietary supplement brand holder FitLife Brands has posted its first quarterly profit in almost two years as it continues to wrestle with a failed acquisition and the struggles of its largest sales platform—GNC.
Kerry Group has cemented its long-standing ties with India by contributing €500,000 to fund a new wing at the Noon Hospital and Research Centre in Rajasthan, India, as part of a five-year support programme.
Network marketing company Mannatech says it is rounding the corner on business disruptions caused by changes made to better comply with US laws against pyramid schemes.
Some dietary supplement ingredients have landed on US President Donald Trump’s proposed list of tariffs on imported Chinese goods. They include CoQ10 and vitamins E, B2 and B12.
Australia's new 'ground-breaking' supplement regulations will stand the sector in good stead for the next 30 years, according to the CEO of national trade body Complementary Medicines Australia (CMA).
GlaxoSmithKline could look to sell some – or all – of its nutrition portfolio to help fund the €10.5 billion acquisition of Novartis’ stake in their consumer-health joint venture.
Nature's Sunshine has emerged from the cloud cast by a software implementation debacle and a delayed entry to the Chinese market to post a moderately positive year-end earnings report.
An investment fund comprised of key execs formerly behind Swisse Wellness is pumping cash into Elle McPherson's WelleCo brand, with a focus on providing operational leadership, growth in the US and China, and help to boost supply chain and sourcing...
New regulations set to take effect in Brazil will significantly improve market access for dietary ingredients and finished dietary supplements, an expert says.
Balchem Corporation has ridden a string of acquisitions in human nutrition and a rising tide of choline awareness to record results in its most recent earnings statement.
Activist investor Bill Ackman has reportedly exited his short position on Herbalife, ending a high profile, multi-year attempt to drive down the company’s stock price with allegations that its business model constituted an illegal pyramid scheme.
